Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 5/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | BTD | P43251 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12812605 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EALDH1A1HTTVNN1 | |
| SCHEMBL7999234 | 0.80 | KDM4E (0.37) | SMN1; SMN2KDM4EALDH1A1VNN1HPGDS | |
| SCHEMBL16629775 | 0.78 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1VNN1HPGDS | |
| SCHEMBL17445192 | 0.78 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1VNN1HPGDS | |
| Ammonia Solution, Strong SCHEMBL16619952 | 0.76 | KDM4E (0.38) | SMN1; SMN2KDM4EALDH1A1VNN1HPGDS | |
| SCHEMBL19323045 | 0.74 | HTT (0.45) | SMN1; SMN2HTTHPGDS | |
| SCHEMBL19323055 | 0.74 | HTT (0.45) | SMN1; SMN2HTTHPGDS | |
| SCHEMBL19323011 | 0.74 | HTT (0.45) | SMN1; SMN2HTTHPGDS | |
| SCHEMBL13104826 | 0.74 | RAB9A (0.41) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10115951 | 0.74 | RAB9A (0.41) | SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | SMN1; SMN2 1758/4885KDM4E 4010/4885ALDH1A1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.